Compare TAK & CCEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TAK | CCEP |
|---|---|---|
| Founded | 1781 | 1986 |
| Country | Japan | United Kingdom |
| Employees | 47455 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Beverages (Production/Distribution) |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.5B | 43.1B |
| IPO Year | N/A | 2015 |
| Metric | TAK | CCEP |
|---|---|---|
| Price | $16.66 | $90.00 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $104.33 |
| AVG Volume (30 Days) | ★ 2.9M | 1.4M |
| Earning Date | 05-13-2026 | 02-17-2026 |
| Dividend Yield | ★ 3.24% | 2.48% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.16 | $4.86 |
| Revenue Next Year | $1.22 | $3.79 |
| P/E Ratio | $41.25 | ★ $20.93 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.99 | $84.66 |
| 52 Week High | $18.90 | $110.90 |
| Indicator | TAK | CCEP |
|---|---|---|
| Relative Strength Index (RSI) | 41.51 | 35.41 |
| Support Level | $16.24 | $86.15 |
| Resistance Level | $16.92 | $93.00 |
| Average True Range (ATR) | 0.22 | 2.04 |
| MACD | 0.05 | -0.46 |
| Stochastic Oscillator | 68.62 | 4.77 |
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
CCEP is the second-largest bottling partner in the Coca-Cola system by volume, behind Coca-Cola Femsa, and primarily operates in developed Europe, Australasia, and Southeast Asia. In 2025, CCEP sold 3.9 billion unit cases of beverages, which we estimate equates to roughly 9% of the global Coke system volume.TCCC owns 19% of the equity of CCEP, Olive Partners, a holding company of bottling operations, owns a further 36%, and the remaining 45% is free float.